Eli Lilly and Company (LLY) Competitors

Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Is LLY or AMGN a better dividend stock?

Eli Lilly and Company pays an annual dividend of $6.00 per share and has a dividend yield of 0.8%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.3%. Eli Lilly and Company pays out 39.2% of its earnings in the form of a dividend. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Eli Lilly and Company has increased its dividend for 11 consecutive years and Amgen has increased its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Do institutionals & insiders have more ownership in LLY or AMGN?

82.5% of Eli Lilly and Company shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.1% of Eli Lilly and Company shares are held by insiders. Comparatively, 0.8% of Amgen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Is LLY or AMGN more profitable?

Eli Lilly and Company has a net margin of 25.91% compared to Amgen's net margin of 18.96%. Amgen's return on equity of 174.71% beat Eli Lilly and Company's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eli Lilly and Company	25.91%	92.72%	16.89%
Amgen	18.96%	174.71%	13.12%

Do analysts rate LLY or AMGN?

Eli Lilly and Company presently has a consensus price target of $950.17, suggesting a potential upside of 29.76%. Amgen has a consensus price target of $304.43, suggesting a potential upside of 6.59%. Given Eli Lilly and Company's stronger consensus rating and higher probable upside, research analysts plainly believe Eli Lilly and Company is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eli Lilly and Company	0 Sell rating(s)	9 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.67
Amgen	2 Sell rating(s)	11 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.33

Does the media refer more to LLY or AMGN?

In the previous week, Eli Lilly and Company had 126 more articles in the media than Amgen. MarketBeat recorded 184 mentions for Eli Lilly and Company and 58 mentions for Amgen. Amgen's average media sentiment score of 1.13 beat Eli Lilly and Company's score of 0.66 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eli Lilly and Company	80 Very Positive mention(s)	29 Positive mention(s)	50 Neutral mention(s)	9 Negative mention(s)	15 Very Negative mention(s)	Positive
Amgen	44 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Which has more volatility and risk, LLY or AMGN?

Eli Lilly and Company has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500.

Which has higher earnings and valuation, LLY or AMGN?

Eli Lilly and Company has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eli Lilly and Company	$45.04B	15.39	$10.59B	$15.30	47.86
Amgen	$33.42B	4.60	$4.09B	$12.23	23.35

Summary

Eli Lilly and Company beats Amgen on 13 of the 19 factors compared between the two stocks.